Visualization of network target crosstalk optimizes drug synergism in myocardial ischemia

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Wan, Xiaojing ^a   Meng, Jia ^a   Dai, Yingnan ^a   Zhang, Yina ^a   Yan, Shuang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CAPSAICIN; CASPASE 3; CASPASE 8; CELECOXIB; CURCUMIN; HYDROGEN PEROXIDE; PEPTIDES AND PROTEINS; PROTEIN BAX; PROTEIN BCL2L1; PROTEIN BID; PROTEIN P53; RALOXIFENE; SILIBININ; SULFORAPHANE; TACROLIMUS; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BAC2L1 GENE; BAX GENE; CASP8 GENE; CELL CYCLE REGULATION; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE DENSIFICATION; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; GENE; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HYPOXIA; IN VITRO STUDY; NEWBORN; NONHUMAN; PREDICTIVE VALUE; PROCESS OPTIMIZATION; RAT; TARGET CROSSTALK NETWORK; TP53 GENE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CELLS, CULTURED; CURCUMIN; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MOLECULAR TARGETED THERAPY; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SILYMARIN; SULFONAMIDES;

EID: 84895554358     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088137     Document Type: Article

References (44)

1. Finegold JA, Asaria P, Francis DP (2013) Mortality from ischaemic heart disease by country, region, and age: Statistics from World Health Organisation and United Nations. Int J Cardiol 168: 934-945.
2. Krijnen PA, Nijmeijer R, Meijer CJ, Visser CA, Hack CE, et al. (2002) Apoptosis in myocardial ischaemia and infarction. J Clin Pathol 55: 801-811. (Pubitemid 35331059)
3. Misra MK, Sarwat M, Bhakuni P, Tuteja R, Tuteja N (2009) Oxidative stress and ischemic myocardial syndromes. Med Sci Monit 15: RA209-219.
4. Myerburg RJ, Kessler KM, Mallon SM, Cox MM, deMarchena E, et al. (1992) Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm. N Engl J Med 326: 1451-1455.
5. Ma Y, Halade GV, Lindsey ML (2012) Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res 5: 848-857.
6. Sleight P (2003) Current options in the management of coronary artery disease. Am J Cardiol 92: 4N-8N.
7. Gaziano TA, Galea G, Reddy KS (2007) Scaling up interventions for chronic disease prevention: the evidence. Lancet 370: 1939-1946. (Pubitemid 350192634)
8. Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, et al. (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27: 659-666.
9. Zimmermann GR, Lehár J, Keith CT (2007) Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 12: 34-42. (Pubitemid 46014485)
10. Denke MA (2004) Coadministration of multidrug therapy to achieve lipid goals. J Am Osteopath Assoc 104: S17-S22.
11. Eghdamian B, Ghose K (1998) Mode of action and adverse effects of lipid lowering drugs. Drugs Today (Barc) 34: 943-956. (Pubitemid 29079256)
12. Manikandan P, Sumitra M, Aishwarya S, Manohar BM, Lokanadam B, et al. (2004) Curcumin modulates free radical quenching in myocardial ischaemia in rats. Int J Biochem Cell Biol 36: 1967-1980.
13. D'Alonzo AJ, Grover GJ, Darbenzio RB, Hess TA, Sleph PG, et al. (1995) In vitro effects of capsaicin: antiarrhythmic and antiischemic activity. Eur J Pharmacol 272: 269-278.
14. Zhao M, He X, Zhao M, Bi XY, Zhang HL, et al. (2012) Low-dose celecoxib improves coronary function after acute myocardial ischaemia in rabbits. Clin Exp Pharmacol Physiol 39: 233-240.
15. Chung MT, Cheng PY, Lam KK, Chen SY, Ting YF, et al. (2010) Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats. Menopause 17: 127-134.
16. Ai W, Zhang Y, Tang QZ, Yan L, Bian ZY, et al. (2010) Silibinin attenuates cardiac hypertrophy and fibrosis through blocking EGFR-dependent signaling. J Cell Biochem 110: 1111-1122.
17. Piao CS, Gao S, Lee GH, Kim do S, Park BH, et al. (2010) Sulforaphane protects ischemic injury of hearts through antioxidant pathway and mitochondrial K(ATP) channels. Pharmacol Res 61: 342-348.
18. Squadrito F, Altavilla D, Squadrito G, Saitta A, Deodato B, et al. (2000) Tacrolimus limits polymorphonuclear leucocyte accumulation and protects against myocardial ischaemia- reperfusion injury. J Mol Cell Cardiol 32: 429-440.
19. Ek RO, Yildiz Y, Cecen S, Yenisey C, Kavak T (2008) Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats. Mol Cell Biochem 308: 227-235.
20. Mao X, Wang T, Liu Y, Irwin MG, Ou JS, et al. (2013) N-Acetylcysteine and Allopurinol Confer Synergy in Attenuating Myocardial Ischemia Injury via Restoring HIF-1a/HO-1 Signaling in Diabetic Rats. PLoS One 8: e68949.
21. Higashikuni Y, Takaoka M, Iwata H, Tanaka K, Hirata Y, et al. (2012) Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice. Hypertens Res 35: 62-69.
22. Sunagawa Y, Morimoto T, Wada H, Takaya T, Katanasaka Y, et al. (2011) A natural p300-specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J 75: 2151-2159.
23. Jia J, Zhu F, Ma X, Cao Z, Li Y, et al. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8: 111-128.
24. Li S, Zhang B, Zhang N (2011) Network target for screening synergistic drug combinations with application to traditional Chinese medicine. BMC Syst Biol 5 Suppl 1: S10.
25. Kuhn M, Szklarczyk D, Franceschini A, von Mering C, Jensen LJ, et al. (2012) STITCH 3: zooming in on protein-chemical interactions. Nucleic Acids Res 40: D876-D880.
26. Saito R, Smoot ME, Ono K, Ruscheinski J, Wang PL, et al. (2012) A travel guide to Cytoscape plugins. Nat Methods 9: 1069-1076.
27. Martin A, Ochagavia ME, Rabasa LC, Miranda J, Fernandez-de-Cossio J, et al. (2010) BisoGenet: a new tool for gene network building, visualization and analysis. BMC Bioinformatics 11: 91.
28. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
29. Morris JH, Apeltsin L, Newman AM, Baumbach J, Wittkop T, et al. (2011) clusterMaker: a multi-algorithm clustering plugin for Cytoscape. BMC Bioinformatics 12: 436.
30. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
31. Hakkarainen KM, Hedna K, Petzold M, Hägg S (2012) Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions - a meta-analysis. PLoS One 7: e33236.
32. Leung EL, Cao ZW, Jiang ZH, Zhou H, Liu L (2013) Network-based drug discovery by integrating systems biology and computational technologies. Brief Bioinform 14: 491-505.
33. Mun SH, Joung DK, Kim YS, Kang OH, Kim SB, et al. (2013) Synergistic antibacterial effect of curcumin against methicillin-resistant Staphylococcus aureus. Phytomedicine 20: 714-718.
34. Choudhury D, Ganguli A, Dastidar DG, Acharya BR, Das A, et al. (2013) Apigenin shows synergistic anticancer activity with curcumin by binding at different sites of tubulin. Biochimie 95: 1297-1309.
35. Du Q, Hu B, An HM, Shen KP, Xu L, et al. (2013) Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells. Oncol Rep 29: 1851-1858.
36. Sohma Y, Yu YC, Hwang TC (2013) Curcumin and genistein: the combined effects on disease-associated CFTR mutants and their clinical implications. Curr Pharm Des 19: 3521-3528.
37. Jiang M, Huang O, Zhang X, Xie Z, Shen A, et al. (2013) Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules 18: 701-720.
38. Deters M, Hütten H, Kaever V (2013) Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin. Phytomedicine 20: 120-123.
39. Cho DC, Kim KT, Jeon Y, Sung JK (2012) A synergistic bone sparing effect of curcumin and alendronate in ovariectomized rat. Acta Neurochir (Wien) 154: 2215-2223.
40. Hossain M, Banik NL, Ray SK (2012) Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int 61: 1102-1113.
41. Parasramka MA, Gupta SV (2012) Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells. J Oncol 2012: 709739.
42. Cort A, Timur M, Ozdemir E, Kucuksayan E, Ozben T (2012) Synergistic anticancer activity of curcumin and bleomycin: an in vitro study using human malignant testicular germ cells. Mol Med Rep 5: 1481-1486.
43. Amit I, Wides R, Yarden Y (2007) Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol 3: 151.
44. Poulikakos PI, Solit DB (2011) Resistance to MEK inhibitors: should we co-target upstream? Sci Signal 4: pe16.